

Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/089,024	LEHMANN-LINTZ ET AL.
	Examiner	Art Unit
	Emily Bernhardt	1624

All Participants:

Status of Application: _____

(1) Emily Bernhardt. (3) _____.

(2) Mr. Anthony Bottino. (4) _____.

Date of Interview: 27 July 2004

Time: _____

Type of Interview:

Telephonic
 Video Conference
 Personal (Copy given to: Applicant Applicant's representative)

Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description: _____

Part I.

Rejection(s) discussed:

Claims discussed:

11 in particular

Prior art documents discussed:

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

In urging support for newly added rings it was pointed out to counsel that "thiazolyl" is not exemplified in eg.38 but rather 1,2,4 thiadiazolyl. It was agreed to replace the former with the latter ring in claim 11 via an Examiner's Amendment.

Part III.

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Bottino on July 27,2004.

1. In claim 11 on p.2 on the 8th line, delete "thiazolyl" and insert in its place
- - - 1,2,4 thiadiazolyl - - - .

2. In claim 11 on p.3 on the 5th line, delete "thiazolyl" and insert in its place
- - - 1,2,4 thiadiazolyl - - - .

The following word processing typo is also being corrected:

3. In claim 11 on p.3 on the 8th line after "R_f denotes" delete "–" .

Cusic (US'509) cited in applicants' IDS filed 3/14/02 was inadvertently not considered and so is cited on a PTO-892 accompanying this action.

Bernhardt:eb

(571)272-0664

Application/Control Number: 10/089,024
Art Unit: 1624

Page 3

8/2/04

E Bernhardt

EMILY BERNHARDT
PRIMARY EXAMINER
GROUP 120-1600